The lack of trade-off between conformational stability and binding affinity in a nanobody with therapeutic potential for a misfolding disease.

Abstract excerpt

To improve protein pharmaceuticals, we need to balance protein stability and binding affinity with in vivo efficiency. We have recently developed a nanobody (NB-AGT-2) against the alanine:glyoxylate aminotransferase with high stability (Tm ∼ 86 °C) that may be useful to treat a misfolding disease called primary hyperoxaluria type 1. In this work, we characterize the relationships between protein stability and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Models, Molecular
• Share to Mutation